Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Lung Cancer (Amsterdam, Netherlands)|November 14, 2021
Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohortNicolas Girard, Maurice Perol, Gaëtane Simon, et al.
Bulletin Du Cancer|October 9, 2024
[Precision medicine in oncology: A reality… without equity]Frédérique Pénault-Llorca, Clarisse Audigier-Valette, Pierre-Jean Lamy, et al.
Journal of Thoracic Disease|December 23, 2017
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC GroupHervé Le Caer, Isabelle Borget, Romain Corre, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2024
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trialJean Baptiste Oudart, Simon Garinet, Caroline Leger, et al.
JTO Clinical and Research Reports|September 30, 2021
Development and Validation of a Simplified Prognostic Score in SCLCElodie Negre, Amandine Coffy, Alexandra Langlais, et al.
Oncoimmunology|April 15, 2025
Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancerFabrice Barlesi, Adrien Dixmier, Didier Debieuvre, et al.
The European Respiratory Journal|May 24, 2020
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trialArmelle Lavole, Laurent Greillier, Julien Mazières, et al.
Lung Cancer (Amsterdam, Netherlands)|August 13, 2013
Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study)Alain Vergnenègre, Stéphane Hominal, Achille Edem Tchalla, et al.
The Lancet. Respiratory Medicine|November 1, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 studyHervé Léna, Laurent Greillier, Claire Cropet, et al.
Lung Cancer (Amsterdam, Netherlands)|June 11, 2015
Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study)Denis Moro-Sibilot, Clarisse Audigier-Valette, Patrick Merle, et al.
Pageof 9